lidocaine + halobetasol propionate

A topical **fixed-dose combination drug** containing *lidocaine*, a local anesthetic, and *halobetasol propionate*, a superpotent topical corticosteroid. **Lidocaine** acts by blocking voltage-gated sodium channels in neuronal cell membranes, preventing the initiation and conduction of nerve impulses, thus providing local anesthesia. **Halobetasol propionate** reduces inflammation, erythema, and pruritus by activating glucocorticoid receptors and modulating gene expression to suppress the production of inflammatory mediators. The combination is designed to provide both rapid symptomatic relief (from lidocaine) and potent anti-inflammatory effects (from halobetasol) in skin conditions. While halobetasol propionate combination products with other actives (such as tazarotene) are approved for plaque psoriasis, the specific pairing with lidocaine is uncommon and there are no prominent branded formulations widely approved in major markets as of the knowledge cutoff date.

Brand names

Halo-Lido

Other names

halobetasol and lidocaine combination therapyCITI-002CITI002CITI 002Halo-Lido